Matthew Kyle Martin

US Patent:

7435823, Oct 14, 2008

Filed:

Jan 24, 2005

Appl. No.:

11/042634

Inventors:

Michele Potashman - Cambridge MA, US
Steven Bellon - Wellesley MA, US
Shon Booker - Thousand Oaks CA, US
Yuan Cheng - Newbury Park CA, US
Joseph L. Kim - Wayland MA, US
Andrew Tasker - Simi Valley CA, US
Ning Xi - Thousand Oaks CA, US
Shimin Xu - Ventura CA, US
Jean-Christophe Harmange - Andover MA, US
George Borg - Cambridge MA, US
Matthew Weiss - Boston MA, US
Brian L. Hodous - Cambridge MA, US
Russell Graceffa - Hampton NH, US
William H. Buckner - Arlington MA, US
Craig E. Masse - Cambridge MA, US
Deborah Choquette - Medford MA, US
Matthew W. Martin - Cambridge MA, US
Julie Germain - Medford MA, US
Lucian V. DiPietro - Gloucester MA, US
Stuart C. Chaffee - Cambridge MA, US
Joseph J. Nunes - Andover MA, US
John L. Buchanan - Brookline MA, US
Gregory J. Habgood - Merrimac MA, US
David C. McGowan - Woluwe St. Pierre, BE
Douglas A. Whittington - Waltham MA, US
Daniel La - Brookline MA, US
Vinod F. Patel - Acton MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 215/38
C07D 265/34

US Classification:

546153, 546 15, 544 99, 544105

Abstract:

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

7442698, Oct 28, 2008

Filed:

Jul 13, 2004

Appl. No.:

10/891636

Inventors:

John L. Buchanan - Brookline MA, US
Daniel Elbaum - Newton MA, US
Matthew W. Martin - Cambridge MA, US
David C. McGowan - Arlington MA, US
Perry M. Novak - Milford MA, US
Joseph J. Nunes - Andover MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 239/48
C07D 403/12
A61K 31/505

US Classification:

5142358, 51425214, 514275, 544122, 544295, 544323

Abstract:

The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I:.

US Patent:

7674907, Mar 9, 2010

Filed:

Jul 18, 2005

Appl. No.:

11/184237

Inventors:

Joseph J. Nunes - Andover MA, US
Matthew W. Martin - Cambridge MA, US
Ryan White - Somerville MA, US
David McGowan - Woluwe St. Pierre, BE
Jean E. Bemis - Arlington MA, US
Frank Kayser - San Francisco CA, US
Jiasheng Fu - Foster City CA, US
Jinqian Liu - Palo Alto CA, US
XianYun Jiao - San Mateo CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 491/048
A61K 31/4355

US Classification:

546115, 546116, 514302

Abstract:

The present invention relates to furanopyridine compounds having the general Formula I:.

US Patent:

7754717, Jul 13, 2010

Filed:

Aug 11, 2006

Appl. No.:

11/503551

Inventors:

Erin F. Dimauro - Cambridge MA, US
Jean E. Bemis - Arlington MA, US
Stuart C. Chaffee - Philadelphia PA, US
Ning Chen - Thousand Oaks CA, US
Essa Hu - Camarillo CA, US
Roxanne Kunz - Santa Monica CA, US
Matthew W. Martin - Cambridge MA, US
David C. McGowan - Woluwe St. Pierre, BE
Shannon Rumfelt - Camarillo CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A01N 43/60
A01N 43/54
A01N 43/42
A61K 31/495
A61K 31/50
A61K 31/501
A61K 31/4965
A61K 31/51
A61K 31/47
C07D 239/42
C07D 401/04
C07D 237/30
C07D 401/00

US Classification:

514248, 51425203, 51425205, 514249, 51425505, 514256, 514300, 514314, 544237, 544238, 544333, 544353, 544405

Abstract:

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I.

US Patent:

7776869, Aug 17, 2010

Filed:

Oct 14, 2005

Appl. No.:

11/251490

Inventors:

Stuart C. Chaffee - Cambridge MA, US
Brian K. Albrecht - Cambridge MA, US
Brian L. Hodous - Cambridge MA, US
Matthew W. Martin - Arlington MA, US
David C. McGowan - Woluwe Street Pierre, BE
Erin F. DiMauro - Cambridge MA, US
Gade Reddy - Newbury Park CA, US
Victor J. Cee - Mansfield MA, US
Philip R. Olivieri - Medford MA, US
Anthony Reed - Oxnard CA, US
Karina Romero - Cambridge MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 239/38
C07D 239/42
A61K 31/505
A61K 31/506
A61P 35/00

US Classification:

514269, 514275, 544299, 544309, 544317, 544320, 544321, 544323, 544324

Abstract:

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I.

US Patent:

7795254, Sep 14, 2010

Filed:

Oct 28, 2008

Appl. No.:

12/290223

Inventors:

Jean-Christophe Harmange - Andover MA, US
Matthew W. Martin - Arlington MA, US
Yohannes Teffera - Topsfield MA, US
Raju Subramanian - Thousand Oaks CA, US
Ryan White - Somerville MA, US
Roger Zanon - Minneapolis MN, US
Jay Larrow - Wakefield MA, US
Joseph F. Payack - Somerset NJ, US
Mina Dilmeghani Seran - Ankara, TR

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

C07D 413/12
A61K 31/538

US Classification:

5142305, 544105

Abstract:

Selected benzomorpholine compounds, including 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(5 -methyl-3-isoxazolyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide, are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

8178557, May 15, 2012

Filed:

Jun 9, 2008

Appl. No.:

12/157303

Inventors:

Michele Potashman - Cambridge MA, US
Steven Bellon - Wellesley MA, US
Shon Booker - Thousand Oaks CA, US
Yuan Cheng - Newbury Park CA, US
Joseph L. Kim - Wayland MA, US
Andrew Tasker - Simi Valley CA, US
Ning Xi - Thousand Oaks CA, US
Shimin Xu - San Diego CA, US
Jean-Christophe Harmange - Andover MA, US
George Borg - Somerville MA, US
Matthew Weiss - Boston MA, US
Brian L. Hodous - Cambridge MA, US
Russell Graceffa - Hampton NH, US
William H. Buckner - Kittery ME, US
Craig E. Masse - Cambridge MA, US
Deborah Choquette - Medford MA, US
Matthew W. Martin - Arlington MA, US
Julie Germain - Quebec, CA
Lucian V. DiPietro - Gloucester MA, US
Stuart C. Chaffee - Boston MA, US
Joseph J. Nunes - Andover MA, US
John L. Buchanan - Newton MA, US
David C. McGowan - Brussels, BE
Douglas A. Whittington - Waltham MA, US
Gregory J. Habgood - Merrimac MA, US
Vinod F. Patel - Acton MA, US
Daniel La - Brookline MA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/04

US Classification:

514312

Abstract:

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

US Patent:

8492404, Jul 23, 2013

Filed:

May 26, 2010

Appl. No.:

12/788201

Inventors:

Matthew W. Martin - Arlington MA, US
David C. McGowan - Brussels, BE

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A01N 43/42
A61K 31/47
C07D 215/46

US Classification:

514313, 546162

Abstract:

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I.